DrugPatentWatch Database Preview

Msd Merck Co Company Profile

« Back to Dashboard

What is the competitive landscape for MSD MERCK CO, and when can generic versions of MSD MERCK CO drugs launch?

MSD MERCK CO has four approved drugs.

There are two US patents protecting MSD MERCK CO drugs.

There are eighty-six patent family members on MSD MERCK CO drugs in forty-four countries and seventeen supplementary protection certificates in seven countries.

Summary for Msd Merck Co

International Patents:	86
US Patents:	2
Tradenames:	3
Ingredients:	3
NDAs:	4

Drugs and US Patents for Msd Merck Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	ZOCOR	simvastatin	TABLET;ORAL	019766-005	Jul 10, 1998	AB	RX	Yes	Yes
Msd Merck Co	EMEND	aprepitant	FOR SUSPENSION;ORAL	207865-001	Dec 17, 2015		RX	Yes	Yes
Msd Merck Co	ZOCOR	simvastatin	TABLET;ORAL	019766-002	Dec 23, 1991	AB	RX	Yes	No
Msd Merck Co	EMEND	aprepitant	FOR SUSPENSION;ORAL	207865-001	Dec 17, 2015		RX	Yes	Yes	8,258,132		Y

Expired US Patents for Msd Merck Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Merck Co	ZOCOR	simvastatin	TABLET;ORAL	019766-002	Dec 23, 1991	4,444,784*PED
Msd Merck Co	SINGULAIR	montelukast sodium	TABLET;ORAL	020829-002	Feb 20, 1998	5,565,473*PED
Msd Merck Co	SINGULAIR	montelukast sodium	TABLET, CHEWABLE;ORAL	020830-002	Mar 3, 2000	5,565,473*PED
Msd Merck Co	ZOCOR	simvastatin	TABLET;ORAL	019766-005	Jul 10, 1998	RE36481*PED

Paragraph IV (Patent) Challenges for MSD MERCK CO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsule	40 mg, 80 mg and 125 mg		2008-11-03
	Injection	150 mg/vial		2012-01-25
	Tablets	10 mg		2007-02-20
	Injection	115 mg/vial		2012-01-25
	for Oral Suspension	125 mg/Kit		2016-11-23
	Chewable Tablets	4 mg and 5 mg		2006-12-26

Non-Orange Book US Patents for Msd Merck Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,583,142	Polymorphic form of a tachykinin receptor antagonist
6,229,010	Polymorphic form of a tachykinin receptor antagonist
6,432,953	Polymorphic form of a tachykinin receptor antagonist

International Patents for Msd Merck Co Drugs

Country	Document Number	Estimated Expiration
South Africa	9805765
Slovakia	187299
Taiwan	577887
Canada	2469315

Supplementary Protection Certificates for Msd Merck Co Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90009	Netherlands		PRODUCT NAME: MONTELUKASTUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NATRII MONTELUKASTUM; NATL REGISTRATION NO/DATE: RVG 23164 AND RVG 23165 19981103; FIRST REGISTRATION: FI 12766 AND 12767 19970825
2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C0022	France		PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Msd Intl
• Msd Intl Gmbh
• Msd Merck Co